HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Scott M Gianino Selected Research

Optic Nerve Glioma

1/2016NF1 germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1.
6/2015Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.
5/2015The impact of coexisting genetic mutations on murine optic glioma biology.
2/2013Reduced microglial CX3CR1 expression delays neurofibromatosis-1 glioma formation.
2/2011Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.
1/2011Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth.
7/2010Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.
4/2010Defective cAMP generation underlies the sensitivity of CNS neurons to neurofibromatosis-1 heterozygosity.
12/2008Increased c-Jun-NH2-kinase signaling in neurofibromatosis-1 heterozygous microglia drives microglia activation and promotes optic glioma proliferation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Scott M Gianino Research Topics

Disease

9Optic Nerve Glioma
01/2016 - 12/2008
7Glioma (Gliomas)
06/2015 - 02/2010
6Neoplasms (Cancer)
06/2015 - 02/2010
4Neurofibromatosis 1 (Neurofibromatosis Type I)
08/2015 - 08/2009
2Brain Neoplasms (Brain Tumor)
10/2013 - 09/2011
1Neurodevelopmental Disorders
08/2015
1Memory Disorders (Memory Loss)
02/2014
1Astrocytoma (Pilocytic Astrocytoma)
10/2013
1Tuberous Sclerosis (Bourneville's Disease)
09/2011
1Crush Injuries
04/2010
1Neurofibrosarcoma (MPNST)
02/2010

Drug/Important Bio-Agent (IBA)

5Neurofibromin 1 (Neurofibromin)IBA
08/2015 - 02/2010
4TOR Serine-Threonine KinasesIBA
06/2015 - 02/2010
2RolipramIBA
07/2010 - 04/2010
1NeomycinFDA LinkGeneric
01/2016
1Glial Fibrillary Acidic ProteinIBA
01/2016
1Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
06/2015
1Retinaldehyde (Retinal)IBA
05/2015
1Biological ProductsIBA
05/2015
1Dopamine (Intropin)FDA LinkGeneric
02/2014
1Proto-Oncogene Proteins B-rafIBA
10/2013
1Chemokine ReceptorsIBA
02/2013
1trans-sodium crocetinate (crocetin)IBA
09/2011
1Jagged-1 ProteinIBA
02/2011
1Biomarkers (Surrogate Marker)IBA
02/2011
1Sirolimus (Rapamycin)FDA Link
02/2011
1Ganciclovir (Cytovene)FDA LinkGeneric
01/2011
1plerixaforFDA Link
07/2010
1Phosphodiesterase 4 InhibitorsIBA
07/2010
1cucurbitacin IIBA
02/2010
1Cyclin D1IBA
02/2010
1RNA (Ribonucleic Acid)IBA
08/2009
1Proteins (Proteins, Gene)FDA Link
08/2009
1pyrazolanthroneIBA
12/2008

Therapy/Procedure

5Therapeutics
06/2015 - 02/2010